Human Microbiome Modulators Market Size To Be Worth USD 5.24 Billion by 2027 Growing at a CAGR of 16.5% | Emergen Research
December 22, 2020 08:33 ET
|
Emergen Research
Vancouver, British Columbia, Dec. 22, 2020 (GLOBE NEWSWIRE) -- The Global Human Microbiome Modulators Market is forecast to be worth USD 5.24 Billion by 2027, according to the current analysis by...
“Global Dermatological Drugs Market Set to Grow To $36bn by 2024”, according to Visiongain
May 15, 2019 06:41 ET
|
Visiongain Ltd
Visiongain has launched a new pharma report Top 25 Dermatological Drugs Manufacturers 2019: Galderma, Johnson & Johnson, AbbVie, GlaxoSmithKline, Pfizer, Novartis, Eli Lilly, Mylan and Other...
Biofrontera reports preliminary unaudited sales revenue for the first three months of 2019
April 15, 2019 06:15 ET
|
Biofrontera AG
Leverkusen, Germany, April 15, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reports...
Changes in the composition of the Supervisory Board
March 27, 2019 09:05 ET
|
Biofrontera AG
Leverkusen, Germany, March 27, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that the...
Biofrontera reports earnings results for the third quarter and first nine months of 2018
November 16, 2018 02:20 ET
|
Biofrontera AG
Leverkusen, Germany, Nov. 16, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its...
Biofrontera Announces Conference Call to Discuss Q3 2018 Financial Results
November 05, 2018 06:26 ET
|
Biofrontera AG
Leverkusen, Germany, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its...
Biofrontera Reports First Quarter 2018 Financial Results
May 30, 2018 08:00 ET
|
Biofrontera AG
Leverkusen, Germany, May 30, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its...
Biofrontera Reports Full Year 2017 Financial Results
April 30, 2018 08:00 ET
|
Biofrontera AG
Leverkusen, Germany, April 30, 2018 (GLOBE NEWSWIRE) --
Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical...
AXIM Biotech Files Patent Application on Product Formulation Comprised of Cannabinoids With Anti-Bacterial and Anti-Fungal Activities
April 18, 2018 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, April 18, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech), (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the European Patent...
Biofrontera announces preliminary unaudited sales revenues for the 1st Quarter 2018
April 12, 2018 10:53 ET
|
Biofrontera AG
Leverkusen, Germany, April 12, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA) (ISIN: DE0006046113), the specialist for the treatment of sun-induced skin cancer, today announced preliminary...